Tumor-associated antigen TAG-72: Correlation of expression in primary and metastatic breast carcinoma lesions
- 1 February 1985
- journal article
- research article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 6 (1), 49-56
- https://doi.org/10.1007/bf01806010
Abstract
Variability of tumor-associated antigens among and within human tumor cell groups presents a potential problem in the development and optimization of immunodiagnostic and therapeutic procedures for cancer. We determined the degree of expression of a tumor-associated antigen in the primary and metastatic lesions of 23 patients with infiltrating ductal carcinoma; this was accomplished using monoclonal antibody B72.3, an IgG1 generated against membrane-enriched fractions of human metastatic breast carcinomas and reactive with a 220,000–400,000 d glycoprotein complex, termed TAG-72, and the avidin-biotin complex immunoperoxidase method on fixed tissue sections. Sixteen of the 23 breast carcinomas (70%) demonstrated MAb B72.3 reactivity (range 5% to 100% of tumor cells staining). Reactivity of lymph node metastases was present in 14 of 21 patients (67%). MAb reactivity in metastases to distant sites, including bone, adrenals, liver, skin and effusions, was present in 10 of 18 patients (56%). In one patient, neither the primary carcinoma nor the metastasis to the lymph node demonstrated reactivity. There was a statistically significant positive correlation between MAb B72.3 reactivity in both primary and lymph node metastases (Kendall's Correlation Coefficient = 0.60, p = 0.0006) and between lymph node and distant metastases (Kendall's Correlation Coefficient = 0.48, p = 0.02) of the same patient. No correlation existed between antibody reactivity seen in the primary and that found in the distant lesions of that patient. These studies thus demonstrate that monoclonal antibody B72.3 can detect expression of a tumor-associated antigen in both primary and metastatic infiltrating ductal carcinoma lesions, and may prove valuable in the understanding of tumor biology of metastases and as a means for diagnosing occult disease.This publication has 10 references indexed in Scilit:
- USE OF A MONOCLONAL-ANTIBODY (B72.3) AS AN IMMUNOCYTOCHEMICAL ADJUNCT TO DIAGNOSIS OF ADENOCARCINOMA IN HUMAN EFFUSIONS1985
- PATTERNS OF REACTIVITY OF 4 NOVEL MONOCLONAL-ANTIBODIES (B72.3, DF3, B1.1 AND B6.2) WITH CELLS IN HUMAN-MALIGNANT AND BENIGN EFFUSIONS1984
- Cancer Statistics, 1984CA: A Cancer Journal for Clinicians, 1984
- Differential reactivity of monoclonal antibodies with human colon adenocarcinomas and adenomasInternational Journal of Cancer, 1983
- DEFINITION OF ANTIGENIC HETEROGENEITY AND MODULATION AMONG HUMAN MAMMARY-CARCINOMA CELL-POPULATIONS USING MONOCLONAL-ANTIBODIES TO TUMOR-ASSOCIATED ANTIGENS1983
- Differential Binding to Human Mammary and Nonmammary Tumors of Monoclonal Antibodies Reactive with Carcinoembryonic AntigenCancer Investigation, 1983
- A monoclonal antibody (B72.3) defines patterns of distribution of a novel tumor‐associated antigen in human mammary carcinoma cell populationsInternational Journal of Cancer, 1982
- A spectrum of monoclonal antibodies reactive with human mammary tumor cells.Proceedings of the National Academy of Sciences, 1981
- Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.Journal of Histochemistry & Cytochemistry, 1981
- The pathology of invasive breast cancerA Syllabus Derived from Findings of the National Surgical Adjuvant Breast Project (Protocol No. 4)Cancer, 1975